Literature DB >> 30406762

Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Edwin A Takahashi1, David F Kallmes1, Kristin C Mara2, William S Harmsen3, Sanjay Misra4.   

Abstract

PURPOSE: We aimed to determine the incidence rate and potential risk factors for postcontrast acute kidney injury (PC-AKI) as well as the long-term clinical implications on dialysis and mortality in patients with chronic kidney disease (CKD) who underwent renal artery stent placement exclusively with gadolinium-based contrast agents.
METHODS: This retrospective study reviewed 412 patients with CKD who underwent renal artery stent placement. Sixty-eight patients underwent intervention exclusively with gadolinium-based contrast agents and were analyzed. Criteria for PC-AKI included either an absolute serum creatinine increase >0.3 mg/dL or percentage increase in serum creatinine >50% within 48 hours of intervention. Logistic regression analysis was performed to identify risk factors for PC-AKI. The cumulative proportion of patients who died or went on to hemodialysis was determined using Kaplan-Meier survival analysis.
RESULTS: The incidence of PC-AKI was 14.7%. The rate of AKI decreased for every 1 unit increase in glomerular filtration rate ( GFR, odds ratio [OR]=0.91, P = 0.047). Prehydration was associated with a lower PC-AKI rate (OR=0.17; P = 0.015). Acute kidney injury after intervention was associated with an increased rate of dialysis (Hazard ratio [HR]=4.51, P = 0.002) and mortality (HR=2.52; P = 0.027).
CONCLUSION: Gadolinium-based contrast agents are potentially nephrotoxic when used for endovascular intervention in patients with CKD. The risk of PC-AKI increased with lower GFR and decreased with prehydration. Dialysis and mortality risk were increased in patients who developed PC-AKI.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30406762      PMCID: PMC6223820          DOI: 10.5152/dir.2018.18172

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  34 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

2.  Acute renal failure after arteriography with a gadolinium-based contrast agent.

Authors:  J Gemery; B Idelson; S Reid; E K Yucel; H Pagan-Marin; S Ali; L Casserly
Journal:  AJR Am J Roentgenol       Date:  1998-11       Impact factor: 3.959

3.  Intrarenal oxygenation by blood oxygenation level-dependent MRI in contrast nephropathy model: effect of the viscosity and dose.

Authors:  Lu-Ping Li; Tammy Franklin; Hongyan Du; Maria Papadopoulou-Rosenzweig; Joann Carbray; Richard Solomon; Pottumarthi V Prasad
Journal:  J Magn Reson Imaging       Date:  2012-07-23       Impact factor: 4.813

4.  Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention.

Authors:  Mitsuru Abe; Takeshi Morimoto; Masaharu Akao; Yutaka Furukawa; Yoshihisa Nakagawa; Satoshi Shizuta; Natsuhiko Ehara; Ryoji Taniguchi; Takahiro Doi; Kei Nishiyama; Neiko Ozasa; Naritatsu Saito; Kozo Hoshino; Hirokazu Mitsuoka; Masanao Toma; Toshihiro Tamura; Yoshisumi Haruna; Toru Kita; Takeshi Kimura
Journal:  Am J Cardiol       Date:  2014-05-16       Impact factor: 2.778

5.  Gadolinium-based contrast agents as an alternative at vena cavography in patients with renal insufficiency--early experience.

Authors:  J A Kaufman; S C Geller; H Bazari; A C Waltman
Journal:  Radiology       Date:  1999-07       Impact factor: 11.105

Review 6.  Contrast alternatives for iodinated contrast allergy and renal dysfunction: options and limitations.

Authors:  Gregory J Nadolski; S William Stavropoulos
Journal:  J Vasc Surg       Date:  2012-12-14       Impact factor: 4.268

Review 7.  Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.

Authors:  Mark A Perazella
Journal:  Curr Drug Saf       Date:  2008-01

8.  Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.

Authors:  Albert D Sam; Mark D Morasch; Jeremy Collins; Gina Song; Richard Chen; F Scott Pereles
Journal:  J Vasc Surg       Date:  2003-08       Impact factor: 4.268

Review 9.  Contrast-induced nephropathy: what are the true clinical consequences?

Authors:  Michael Rudnick; Harold Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

10.  Estimating the Risk of Radiocontrast-Associated Nephropathy.

Authors:  Emilee Wilhelm-Leen; Maria E Montez-Rath; Glenn Chertow
Journal:  J Am Soc Nephrol       Date:  2016-09-29       Impact factor: 10.121

View more
  1 in total

Review 1.  Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.

Authors:  Jeffrey C Weinreb; Roger A Rodby; Jerry Yee; Carolyn L Wang; Derek Fine; Robert J McDonald; Mark A Perazella; Jonathan R Dillman; Matthew S Davenport
Journal:  Kidney Med       Date:  2020-11-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.